Document is current
Any future updates will be listed below
-
Authors
Kajikawa, Masato
Maruhashi, Tatsuya
Hidaka, Takayuki
Matsui, Shogo
Hashimoto, Haruki
Takaeko, Yuji
Nakano, Yukiko
Kurisu, Satoshi
Kihara, Yasuki
Yusoff, Farina Mohamad
Kishimoto, Shinji https://orcid.org/0000-0002-5109-7805
Chayama, Kazuaki
Goto, Chikara
Noma, Kensuke
Nakashima, Ayumu https://orcid.org/0000-0002-7838-1494
Hiro, Takafumi
Hirayama, Atsushi
Shiina, Kazuki
Tomiyama, Hirofumi
Yagi, Shusuke
Amano, Rie
Yamada, Hirotsugu
Sata, Masataka
Higashi, Yukihito
-
Funding
Funding for this research was provided by:
Kyowa Hakko Kirin
- License Information
-
More Information
Article History
Received: 5 March 2019
Accepted: 4 July 2019
First Online: 15 July 2019
Competing Interests
: A.N. received grants from TWOCELLS Co. Ltd., MSD K.K., Astellas Pharma Incorporated, and Teijin Pharma Limited, and honoraria from Kyowa Hakko Kirin Co. Ltd. and CHUGAI Pharmaceutical Co. Ltd. K.N. received honoraria and grants from Daiichi Sankyo Co. Ltd. and MSD K.K., and honoraria from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Amgen Astellas BioPharma K.K., Bayer Holding Limited, Boehringer Ingelheim GmbH, Eli Lilly K.K., Astellas Pharma Incorporated, Toa Eiyo K.K., and Abbott Japan Co. Ltd. H.T. had grants from Teijin Pharma Limited, Asahi Calpis Wellness Company, and Omron Health Care Company. A.H. received consulting fees from Toa-Eiyo Co. Ltd. as well as honoraria from Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corporation, Sanofi K.K., AstraZeneca K.K., Astellas Pharma Incorporated, Daiichi Sankyo Co. Ltd., Amgen Astellas BioPharma K.K., Bayer Pharmaceutical Co., Bristol-Mayer Squibb Pharmaceutical Co. Y.H. received consulting fees from Kyowa Hakko Kirin Corporation related to this study, as well as honoraria and grants from Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Limited, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corporation, Sanofi K.K., AstraZeneca K.K., Kyowa Hakko Kirin Co. Ltd., Takeda Pharmaceutical Co. Ltd., Astellas Pharma Incorporated, Daiichi Sankyo Co. Ltd., Mochida Pharmaceutical Co. Ltd., Nihon Kohden Corporation, Shionogi Co. Ltd., Nippon Sigmax Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Unex Corporation, and Kao Corporation, and honoraria from Radiometer Limited, Omron Corporation, Sumitomo Dainippon Pharma Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Torii Pharmaceutical Co. Ltd., Kowa Co. Ltd., Fujiyakuhin Co. Ltd., Amgen Astellas BioPharma K.K., Nippon Shinyaku Co. Ltd., Itamar Medical Limited, Bayer Holding Limited, Eli Lilly K.K., and Ono Pharmaceutical Co. Ltd. T.H. received honoraria or grants from Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, Sanofi K.K., AstraZeneca K.K., Takeda Pharmaceutical Co. Ltd., Astellas Pharma Incorporated, Daiichi Sankyo Co. Ltd., Mochida Pharmaceutical Co. Ltd., Shionogi Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Kowa Co. Ltd., Amgen Astellas BioPharma K.K., and Ono Pharmaceutical Co. Ltd., MSD K.K., Eisai Co. Ltd., Pfizer Japan Incorporated and Bristol-Myers Squibb Company. Y.K received honoraria from Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Limited, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corporation, Sanofi K.K., Astra Zeneca K.K., Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Kowa Co. Ltd., Nippon Shinyaku Co. Ltd., Bayer Holding Limited, and Ono Pharmaceutical Co. Ltd.
